Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis

Increasing evidence suggests B7-H3 is aberrantly expressed in various cancers, though its prognostic significance in solid tumors remains controversial. We therefore performed a meta-analysis to clarify the prognostic value of B7-H3 expression in human solid tumors. The PubMed and Embase databases were searched, and 28 studies involving 4623 patients were ultimately included in the analysis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were utilized as effect estimates to evaluate the association between B7-H3 expression and overall survival (OS), progressionfree survival (PFS) and recurrence-free survival (RFS). The pooled results showed B7-H3 was associated with poor OS (HR = 1.58; 95% CI: 1.32-1.90; P < 0.00001) and PFS (HR = 1.67; 95% CI: 1.05-2.65; P = 0.031), but not RFS (HR = 1.17; 95% CI: 0.89-1.53; P = 0.267). These results suggest B7-H3 is a negative predictor of OS and PFS in patients with solid tumors. B7-H3 may thus be a useful prognostic biomarker and therapeutic target for human solid tumors. However, further studies will be needed to more precisely determine the prognostic value of B7 H3 expression.